Alzheimer's Disease Therapeutics Market to record USD 3.99 Bn growth — Driven by the availability, research, and development of novel biomarkers

NEW YORK, Sept. 28, 2022 /PRNewswire/ — The global Alzheimer’s disease therapeutics market size is expected to grow by USD 3.99 billion, accelerating at a CAGR of 8.76% between 2021 and 2026, according to the latest research report by Technavio. The report has considered various factors including the patient population, prevalence rate of Alzheimer’s disease, revenue generated by vendors, and disposable income among others to estimate the size of the market. Download PDF Report Sample

The Alzheimer’s disease therapeutics market is fragmented. The market has several approved therapeutics for the symptomatic treatment of Alzheimer’s disease. The strong prevalence of the disease and the need for highly efficacious therapeutics are compelling several vendors to develop new vaccines. Besides, the strong pipeline of novel therapeutics is expected to pave the way for new entrants. Hence, the market is expected to witness the launch of various novel therapeutics and the entry of a few new players during the forecast period. This will intensify the competition in the market and encourage vendors to form strategic alliances to increase their product offerings and geographical reach.

Some of the key vendors operating in the market include the following:

  • AbbVie Inc.: The company offers Alzheimer’s disease therapeutics products such as NAMENDA XR.
  • Aurobindo Pharma Ltd.: The company offers Alzheimer’s disease therapeutics products such as Galantamine Tablets USP 4mg, 8mg, and 12mg.
  • Biogen Inc.: The company operates through one business segment and is involved in discovering, developing, and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases.
  • Eisai Co. Ltd.: The company offers Alzheimer’s disease therapeutics products such as ADUHELM.
  • Eli Lilly and Co.: The company offers Alzheimer’s disease therapeutics products such as TRAILBLAZER-ALZ.

Although the availability, research, and development of novel biomarkers will offer immense growth opportunities, the high cost of therapeutics development will challenge the growth of the market participants. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments. Get detailed insights into market behavior. Buy Report Now

Alzheimer’s Disease Therapeutics Market 2022-2026: Segmentation Analysis

Alzheimer’s Disease Therapeutics Market is segmented as below:

  • Drug Class
    • Cholinesterase Inhibitors
    • N-methyl-D-aspartate Receptor Antagonists
    • Other Drug Class

The market observed high demand for cholinesterase inhibitors from end-users in 2021. Factors such as substantial progress in understanding the basic neurobiology of Alzheimer’s disease and the increased availability of new drugs such as cholinesterase inhibitors are driving the growth of the segment.

  • Geography 
    • North America
    • Europe
    • Asia
    • Rest Of World (ROW)

North America will dominate the growth of the market, occupying 37% of the global market share. The increasing awareness and the strong prevalence of Alzheimer’s disease are driving the growth of the regional market. Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. Our Alzheimer’s disease therapeutics market report covers the following areas:

Alzheimer’s Disease Therapeutics Market 2022-2026: Vendor Analysis

We provide a detailed analysis of around 25 vendors operating in the Alzheimer’s disease therapeutics market, including some of the dominant vendors. Backed with competitive intelligence and benchmarking, our research report on the Alzheimer’s disease therapeutics market is designed to provide entry support, customer profile, and M&As as well as go-to-market strategy support.

Alzheimer’s Disease Therapeutics Market 2022-2026: Key Highlights
  • CAGR of the market during the forecast period 2022-2026
  • Detailed information on factors that will assist Alzheimer’s disease therapeutics market growth during the next five years
  • Estimation of the Alzheimer’s disease therapeutics market size and its contribution to the parent market
  • Predictions on upcoming trends and changes in consumer behavior
  • The growth of the Alzheimer’s disease therapeutics market
  • Analysis of the market’s competitive landscape and detailed information on vendors
  • Comprehensive details of factors that will challenge the growth of Alzheimer’s disease therapeutics market vendors
Related Reports:

Alzheimer’s Disease Therapeutics Market Scope

Report Coverage

Details

Page number

120

Base year

2021

Forecast period

2022-2026

Growth momentum & CAGR

Accelerate at a CAGR of 8.76%

Market growth 2022-2026

USD 3.99 billion

Market structure

Fragmented

YoY growth (%)

8.41

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 37%

Key consumer countries

US, Canada, UK, Germany, Japan, and China

Competitive landscape

Leading companies, competitive strategies, consumer engagement scope

Companies profiled

AB Science SA, AbbVie Inc., AgeneBio Inc., Aurobindo Pharma Ltd., Biogen Inc., Denali Therapeutics Inc., Eisai Co. Ltd., Eli Lilly and Co., Grifols SA, H Lundbeck AS, Johnson and Johnson, Lupin Ltd., Neuronascent Inc., Novartis AG, Shanghai Green Valley Pharmaceuticals Co. Ltd., Spinogenix Inc., T3D Therapeutics Inc., Teva Pharmaceutical Industries Ltd., Viatris Inc., and Vivoryon Therapeutics AG

Market Dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, and market condition analysis for the forecast period.

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Table Of Contents:

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Drug Class
    • Exhibit 06: Executive Summary – Chart on Incremental Growth
    • Exhibit 07: Executive Summary – Data Table on Incremental Growth
    • Exhibit 08: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 09: Parent market
    • Exhibit 10: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 11: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 12: Market segments
  • 3.3 Market size 2021
  • 3.4 Market outlook: Forecast for 2021-2026
    • Exhibit 13: Chart on Global – Market size and forecast 2021-2026 ($ million)
    • Exhibit 14: Data Table on Global – Market size and forecast 2021-2026 ($ million)
    • Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
    • Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

4 Five Forces Analysis

  • 4.1 Five forces summary
    • Exhibit 17: Five forces analysis – Comparison between2021 and 2026
  • 4.2 Bargaining power of buyers
    • Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026
  • 4.3 Bargaining power of suppliers
    • Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026
  • 4.4 Threat of new entrants
    • Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026
  • 4.5 Threat of substitutes
    • Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026
  • 4.6 Threat of rivalry
    • Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026
  • 4.7 Market condition
    • Exhibit 23: Chart on Market condition – Five forces 2021 and 2026

5 Market Segmentation by Drug Class

  • 5.1 Market segments
    • Exhibit 24: Chart on Drug Class – Market share 2021-2026 (%)
    • Exhibit 25: Data Table on Drug Class – Market share 2021-2026 (%)
  • 5.2 Comparison by Drug Class
    • Exhibit 26: Chart on Comparison by Drug Class
    • Exhibit 27: Data Table on Comparison by Drug Class
  • 5.3 Cholinesterase inhibitors – Market size and forecast 2021-2026
    • Exhibit 28: Chart on Cholinesterase inhibitors – Market size and forecast 2021-2026 ($ million)
    • Exhibit 29: Data Table on Cholinesterase inhibitors – Market size and forecast 2021-2026 ($ million)
    • Exhibit 30: Chart on Cholinesterase inhibitors – Year-over-year growth 2021-2026 (%)
    • Exhibit 31: Data Table on Cholinesterase inhibitors – Year-over-year growth 2021-2026 (%)
  • 5.4 N-methyl-D-aspartate receptor antagonist – Market size and forecast 2021-2026
    • Exhibit 32: Chart on N-methyl-D-aspartate receptor antagonist – Market size and forecast 2021-2026 ($ million)
    • Exhibit 33: Data Table on N-methyl-D-aspartate receptor antagonist – Market size and forecast 2021-2026 ($ million)
    • Exhibit 34: Chart on N-methyl-D-aspartate receptor antagonist – Year-over-year growth 2021-2026 (%)
    • Exhibit 35: Data Table on N-methyl-D-aspartate receptor antagonist – Year-over-year growth 2021-2026 (%)
  • 5.5 Other drug class – Market size and forecast 2021-2026
    • Exhibit 36: Chart on Other drug class – Market size and forecast 2021-2026 ($ million)
    • Exhibit 37: Data Table on Other drug class – Market size and forecast 2021-2026 ($ million)
    • Exhibit 38: Chart on Other drug class – Year-over-year growth 2021-2026 (%)
    • Exhibit 39: Data Table on Other drug class – Year-over-year growth 2021-2026 (%)
  • 5.6 Market opportunity by Drug Class
    • Exhibit 40: Market opportunity by Drug Class ($ million)

6 Customer Landscape

  • 6.1 Customer landscape overview
    • Exhibit 41: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

7 Geographic Landscape

  • 7.1 Geographic segmentation
    • Exhibit 42: Chart on Market share by geography 2021-2026 (%)
    • Exhibit 43: Data Table on Market share by geography 2021-2026 (%)
  • 7.2 Geographic comparison
    • Exhibit 44: Chart on Geographic comparison
    • Exhibit 45: Data Table on Geographic comparison
  • 7.3 North America – Market size and forecast 2021-2026
    • Exhibit 46: Chart on North America – Market size and forecast 2021-2026 ($ million)
    • Exhibit 47: Data Table on North America – Market size and forecast 2021-2026 ($ million)
    • Exhibit 48: Chart on North America – Year-over-year growth 2021-2026 (%)
    • Exhibit 49: Data Table on North America – Year-over-year growth 2021-2026 (%)
  • 7.4 Europe – Market size and forecast 2021-2026
    • Exhibit 50: Chart on Europe – Market size and forecast 2021-2026 ($ million)
    • Exhibit 51: Data Table on Europe – Market size and forecast 2021-2026 ($ million)
    • Exhibit 52: Chart on Europe – Year-over-year growth 2021-2026 (%)
    • Exhibit 53: Data Table on Europe – Year-over-year growth 2021-2026 (%)
  • 7.5 Asia – Market size and forecast 2021-2026
    • Exhibit 54: Chart on Asia – Market size and forecast 2021-2026 ($ million)
    • Exhibit 55: Data Table on Asia – Market size and forecast 2021-2026 ($ million)
    • Exhibit 56: Chart on Asia – Year-over-year growth 2021-2026 (%)
    • Exhibit 57: Data Table on Asia – Year-over-year growth 2021-2026 (%)
  • 7.6 Rest of World (ROW) – Market size and forecast 2021-2026
    • Exhibit 58: Chart on Rest of World (ROW) – Market size and forecast 2021-2026 ($ million)
    • Exhibit 59: Data Table on Rest of World (ROW) – Market size and forecast 2021-2026 ($ million)
    • Exhibit 60: Chart on Rest of World (ROW) – Year-over-year growth 2021-2026 (%)
    • Exhibit 61: Data Table on Rest of World (ROW) – Year-over-year growth 2021-2026 (%)
  • 7.7 US – Market size and forecast 2021-2026
    • Exhibit 62: Chart on US – Market size and forecast 2021-2026 ($ million)
    • Exhibit 63: Data Table on US – Market size and forecast 2021-2026 ($ million)
    • Exhibit 64: Chart on US – Year-over-year growth 2021-2026 (%)
    • Exhibit 65: Data Table on US – Year-over-year growth 2021-2026 (%)
  • 7.8 Canada – Market size and forecast 2021-2026
    • Exhibit 66: Chart on Canada – Market size and forecast 2021-2026 ($ million)
    • Exhibit 67: Data Table on Canada – Market size and forecast 2021-2026 ($ million)
    • Exhibit 68: Chart on Canada – Year-over-year growth 2021-2026 (%)
    • Exhibit 69: Data Table on Canada – Year-over-year growth 2021-2026 (%)
  • 7.9 UK – Market size and forecast 2021-2026
    • Exhibit 70: Chart on UK – Market size and forecast 2021-2026 ($ million)
    • Exhibit 71: Data Table on UK – Market size and forecast 2021-2026 ($ million)
    • Exhibit 72: Chart on UK – Year-over-year growth 2021-2026 (%)
    • Exhibit 73: Data Table on UK – Year-over-year growth 2021-2026 (%)
  • 7.10 Germany – Market size and forecast 2021-2026
    • Exhibit 74: Chart on Germany – Market size and forecast 2021-2026 ($ million)
    • Exhibit 75: Data Table on Germany – Market size and forecast 2021-2026 ($ million)
    • Exhibit 76: Chart on Germany – Year-over-year growth 2021-2026 (%)
    • Exhibit 77: Data Table on Germany – Year-over-year growth 2021-2026 (%)
  • 7.11 Japan – Market size and forecast 2021-2026
    • Exhibit 78: Chart on Japan – Market size and forecast 2021-2026 ($ million)
    • Exhibit 79: Data Table on Japan – Market size and forecast 2021-2026 ($ million)
    • Exhibit 80: Chart on Japan – Year-over-year growth 2021-2026 (%)
    • Exhibit 81: Data Table on Japan – Year-over-year growth 2021-2026 (%)
  • 7.12 China – Market size and forecast 2021-2026
    • Exhibit 82: Chart on China – Market size and forecast 2021-2026 ($ million)
    • Exhibit 83: Data Table on China – Market size and forecast 2021-2026 ($ million)
    • Exhibit 84: Chart on China – Year-over-year growth 2021-2026 (%)
    • Exhibit 85: Data Table on China – Year-over-year growth 2021-2026 (%)
  • 7.13 Market opportunity by geography
    • Exhibit 86: Market opportunity by geography ($ million)

8 Drivers, Challenges, and Trends

  • 8.1 Market drivers
  • 8.2 Market challenges
  • 8.3 Impact of drivers and challenges
    • Exhibit 87: Impact of drivers and challenges in 2021 and 2026
  • 8.4 Market trends

9 Vendor Landscape

  • 9.1 Overview
  • 9.2 Vendor landscape
    • Exhibit 88: Overview on Criticality of inputs and Factors of differentiation
  • 9.3 Landscape disruption
    • Exhibit 89: Overview on factors of disruption
  • 9.4 Industry risks
    • Exhibit 90: Impact of key risks on business

10 Vendor Analysis

  • 10.1 Vendors covered
    • Exhibit 91: Vendors covered
  • 10.2 Market positioning of vendors
    • Exhibit 92: Matrix on vendor position and classification
  • 10.3 AbbVie Inc.
    • Exhibit 93: AbbVie Inc. – Overview
    • Exhibit 94: AbbVie Inc. – Product / Service
    • Exhibit 95: AbbVie Inc. – Key offerings
  • 10.4 Aurobindo Pharma Ltd.
    • Exhibit 96: Aurobindo Pharma Ltd. – Overview
    • Exhibit 97: Aurobindo Pharma Ltd. – Product / Service
    • Exhibit 98: Aurobindo Pharma Ltd. – Key offerings
  • 10.5 Eisai Co. Ltd.
    • Exhibit 99: Eisai Co. Ltd. – Overview
    • Exhibit 100: Eisai Co. Ltd. – Business segments
    • Exhibit 101: Eisai Co. Ltd. – Key offerings
    • Exhibit 102: Eisai Co. Ltd. – Segment focus
  • 10.6 Eli Lilly and Co.
    • Exhibit 103: Eli Lilly and Co. – Overview
    • Exhibit 104: Eli Lilly and Co. – Product / Service
    • Exhibit 105: Eli Lilly and Co. – Key offerings
  • 10.7 H Lundbeck AS
    • Exhibit 106: H Lundbeck AS – Overview
    • Exhibit 107: H Lundbeck AS – Product / Service
    • Exhibit 108: H Lundbeck AS – Key offerings
  • 10.8 Johnson and Johnson
    • Exhibit 109: Johnson and Johnson – Overview
    • Exhibit 110: Johnson and Johnson – Business segments
    • Exhibit 111: Johnson and Johnson – Key news
    • Exhibit 112: Johnson and Johnson – Key offerings
    • Exhibit 113: Johnson and Johnson – Segment focus
  • 10.9 Lupin Ltd.
    • Exhibit 114: Lupin Ltd. – Overview
    • Exhibit 115: Lupin Ltd. – Product / Service
    • Exhibit 116: Lupin Ltd. – Key news
    • Exhibit 117: Lupin Ltd. – Key offerings
  • 10.10 Novartis AG
    • Exhibit 118: Novartis AG – Overview
    • Exhibit 119: Novartis AG – Business segments
    • Exhibit 120: Novartis AG – Key offerings
    • Exhibit 121: Novartis AG – Segment focus
  • 10.11 Teva Pharmaceutical Industries Ltd.
    • Exhibit 122: Teva Pharmaceutical Industries Ltd. – Overview
    • Exhibit 123: Teva Pharmaceutical Industries Ltd. – Business segments
    • Exhibit 124: Teva Pharmaceutical Industries Ltd. – Key news
    • Exhibit 125: Teva Pharmaceutical Industries Ltd. – Key offerings
    • Exhibit 126: Teva Pharmaceutical Industries Ltd. – Segment focus
  • 10.12 Viatris Inc.
    • Exhibit 127: Viatris Inc. – Overview
    • Exhibit 128: Viatris Inc. – Business segments
    • Exhibit 129: Viatris Inc. – Key offerings
    • Exhibit 130: Viatris Inc. – Segment focus

11 Appendix

  • 11.1 Scope of the report
  • 11.2 Inclusions and exclusions checklist
    • Exhibit 131: Inclusions checklist
    • Exhibit 132: Exclusions checklist
  • 11.3 Currency conversion rates for US$
    • Exhibit 133: Currency conversion rates for US$
  • 11.4 Research methodology
    • Exhibit 134: Research methodology
    • Exhibit 135: Validation techniques employed for market sizing
    • Exhibit 136: Information sources
  • 11.5 List of abbreviations
    • Exhibit 137: List of abbreviations
About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/alzheimers-disease-therapeutics-market-to-record-usd-3-99-bn-growth–driven-by-the-availability-research-and-development-of-novel-biomarkers-301634253.html

SOURCE Technavio

Alzheimer's Disease Therapeutics Market to record USD 3.99 Bn growth -- Driven by the availability, research, and development of novel biomarkers WeeklyReviewer

PR Newswire Science News

World Reviewer Staff
World Reviewer Staffhttps://weeklyreviewer.com/
The first logical thought has to be "no way". I'm the World Observer! Ill find and share important news all day.

Latest articles

Earnings Disclosure

WeeklyReviewer earns primarily through affiliates and ads. We don’t encourage anyone to click on ads for any other purpose but your own. We recommend products and services often for our readers, and through many we will earn commissions through affiliate programs.

Related articles

WeeklyReviewer